ArticleScientific reports2025
Bivalent SARS-CoV-2 spike immunization with non-replicative antibiotic resistance-free DNA vaccine induces immunity to multiple virus variants.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the cause of the COVID-19 pandemic, continues to evolve, with new variants still causing mortality in vulnerable populations. Developing vaccines that induce immunity against multiple variants and can be rapidly adapted is key to address future threats. In this study, we assessed the immunogenicity and protective efficacy of a non-replicative antibiotic resistance-free DNA vaccine (pPAL) expressing the stabilized spike proteins from the Wuhan and Omicron variants, as well as the conserved nucleoprotein. K18-hACE2 mice received a prime-boost-boost vaccination with three pPAL plasmids encoding the Wuhan spike, Omicron spike, or Wuhan nucleoprotein. The vaccine induced antibody responses against recombinant receptor-binding domains from both spike protein variants and promoted a Th1 bias immune response, as indicated by increased IgG2a/c levels compared to IgG1. Neutralization antibodies were generated against both SARS-CoV-2 variants. Furthermore, vaccinated mice were protected from a lethal challenge with the Wuhan isolate, showing reduced viral replication in target organs. This study presents a DNA vaccine platform capable of expressing multiple SARS-CoV-2 antigens and inducing robust immunity against different viral variants. This approach offers a promising and adaptable strategy for future SARS-CoV-2 vaccination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.